Protalix Biotherapeutics, Inc. (de) · AMEX:PLX

Protalix Biotherapeutics, Inc. (de) — Investor Presentation (August 2026)

16 slides from Protalix Biotherapeutics, Inc. (de)'s investor presentation, August 2026

  1. Slide 1: PDF viewer outline of slide titles

    Thumbnails Document Outline Attachments Slide 1 Slide 2: Forward-Looking Statements Slide 3: Experienced leadership team Slide 4: Accomplished Board of Directors Slide 5: Protalix delivers innovations from concept to market Slide 6: Two commercial products and a growing pipeline for the future Slide

  2. Slide 2: PDF viewer outline of slide titles (continued)

    Slide 14: PRX-115 Phase 2 double blind placebo-controlled study design: actively enrolling Slide 15 Slide 16: Two commercial products sustaining future growth Slide 17: EC and MHRA approve every‑4‑weeks (E4W) Elfabrio® dosing for adults with Fabry disease1 Slide 18: Fabry disease competitive landsca

  3. Slide 3: Protalix BioTherapeutics Corporate Presentation August 2026

    1PROTALIX BIOTHERAPEUTICSC O R P O R A T E P R E S E N T A 2024PROTALIX BIOTHERAPEUTICSPioneeringsolutions to treatment of rare diseasesC O R P O R A T E P R E S E N T A T I O N A u g u s t 2026 2 Forward-Looking Statements Thispresentationcontainsforward- lookingstatementsthatinvolverisksanduncerta

  4. Slide 4: Experienced leadership team

    3 Experienced leadership teamORI KALID, PH.D. VP of R&DDr. Kalid brings >20 years of leadership experience in pharma of SilverskateBio, as well asco-founder and CEO of Pi Therapeutics. He also served at Hotaru Innovation Partners, PREDIX/EPIX Pharmaceuticals and KaryopharmTherapeut has over 20 years

  5. Slide 5: Protalix delivers innovations from concept to market

    5 Protalixdelivers innovations from concept to marketProven execution of for rare diseases with a pipeline for the future1: Elfabriohas been approved for marketing in the United States, the European Union, and additional ma Chiesi Group, is our global partner 2: Elelysois approved in 23 markets. Pfi

  6. Slide 6: Well-capitalized to advance Protalix to the next phase

    7 Well-capitalized to advance Protalixto the next phaseThe Company ach income of $22.1 million for the first half of 20267Elfabrio®sales drove revenues from selling goods up to $19.8 (+$4.4 million from Q2 2025); total revenues climbed to $53.6 million, year to date, from $25.8 million for the same

  7. Slide 7: Key upcoming milestones and catalysts

    20262mg/kg IVevery four weeks(EU)Phase 2 PRX-115 trial actively enrollingQ12026OngoingIncreasing m geographies (organic growth) 9 Phase 2 Actively enrollingPRX-115 in development for u

  8. Slide 8: Uncontrolled gout: limited options and disadvantages with current therapy

    10 Gout and uncontrolled gout •Metabolic disorder characterized by elevated blood urate that ca arthritis and joint damage•Rheumatologists report that ~25% of their patients have above target urat to uncontrolled gout*•Uncontrolled gout is a severe disease with high morbidity and highpain with low u

  9. Slide 9: PRX-115 Phase 1 single ascending dose study: encouraging data

    PRX-115 Phase 1 single ascending dose study: encouraging data 12 2Recombinant PEGylated uricase enzyme produced via ProCellEx® Study SchemePrimary E 12 tolerabilitySecondary Endpoints: PK, PD (uric acid levels)Subjects with elevated uric acidN = 2 placebo in each cohort)Dose escalation meeting by bl

  10. Slide 10: Slide 10

  11. Slide 11: Slide 11

  12. Slide 12: Slide 12

  13. Slide 13: Slide 13

  14. Slide 14: Slide 14

  15. Slide 15: PDF viewer password dialog

    Enter the password to open this PDF file. Cancel OK File name: - File size: - Title: - Author: - Subject: - Keywords: - Creation Date: - Modification Date: - Creator: - PDF Producer: - PDF Version: - Page Count:

  16. Slide 16: PDF viewer document properties

    - Page Size: - Fast Web View: - Close Preparing document for printing… 0% Cancel Choose File No file chosen

Protalix BioTherapeutics — Investor Presentation (August 2026) on 6ix